[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100537943":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":26,"centralContacts":31,"locations":41,"responsibleParty":74,"collaborators":10,"id":77,"slug":10,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":10,"eligibilityCriteria":82,"healthyVolunteers":78,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":10,"studyType":89,"phases":10,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Hospital General de Mexico","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Control Group",null,"Thalidomide 100mg-200mg PO daily alone or in combination with dexamethasone 40mg PO every 24 hours on days 1-4, 8-11 of each cycle.",[13],"Drug: Bortezomib",{"label":15,"type":10,"description":16,"interventionNames":17},"Bortezomib Group","Bortezomib 1.3mg\u002Fm2 SC on days 1,4, 8,11 to the TD scheme for a total of 6 treatment cycles (VTD).",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Bortezomib","Bortezomib 1.3mg\u002Fm2 SC on days 1,4, 8,11 to the TD scheme for a total of 6 treatment cycles (14,15) (VTD)",[15,9],[25],"Intervention Group",[27],{"name":28,"affiliation":29,"role":30},"Adolfo O Martinez Tovar, PhD","Hospital General de México Dr. Eduardo Liceaga","STUDY_DIRECTOR",[32,38],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Christian O Ramos Peñafiel, PhD","CONTACT","+52 55 27892000","2020","leukemiachop33@gmail.com",{"name":39,"role":34,"phone":35,"phoneExt":36,"email":40},"Adán G Gallardo Rodriguez, PhD","nutriologo.agallardo8@gmail.com",[42],{"facility":43,"status":44,"city":45,"state":45,"zip":46,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Hospital General de Mexico Dr. Eduardo Liceaga","RECRUITING","Mexico City","06720","Mexico",{"type":49,"coordinates":50},"Point",[51,52],-99.12766,19.42847,{"lat":52,"lon":51},[55,57,60,63,65,66,68,70,72],{"name":33,"role":34,"phone":56,"phoneExt":10,"email":37},"5523351588",{"name":58,"role":34,"phone":59,"phoneExt":10,"email":40},"Adan G Gallardo Rodriguez","+525584005072",{"name":61,"role":62,"phone":10,"phoneExt":10,"email":10},"Juan M Cano Calderón, MD","SUB_INVESTIGATOR",{"name":64,"role":62,"phone":10,"phoneExt":10,"email":10},"Juan F Zazueta Pozos, MD",{"name":39,"role":62,"phone":10,"phoneExt":10,"email":10},{"name":67,"role":62,"phone":10,"phoneExt":10,"email":10},"Carlos Martínez Murillo, PhD",{"name":69,"role":62,"phone":10,"phoneExt":10,"email":10},"Irma Olarte Carrillo, PhD",{"name":71,"role":62,"phone":10,"phoneExt":10,"email":10},"Adolfo Martínez Tovar, PhD",{"name":33,"role":73,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"type":73,"investigatorFullName":75,"investigatorTitle":76,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Christian Omar Ramos-Peñafiel, MD, PhD","Principal investigator","100537943",false,"NCT06284395","Two Schemes Response in Multiple Myeloma","Bortezomib, Thalidomide, and Dexamethasone Versus Thalidomide and Dexamethasone for Response Rates in Multiple Myeloma Patients: a Retrospective Study","Inclusion Criteria:\n\n* clinical records of patients who were considered eligible for transplant due to their functional status and who were given some treatment strategy comprising a combination of drugs.\n\nExclusion Criteria:\n\n* Incomplete clinical records\n* Clinical records of patients who abandoned treatment or could not continue with the treatment due to economic or distance issues\n* Clinical records of patients who presented severe sepsis before the beginning of either treatment","ALL","18 Years","90 Years",{"count":87,"type":88},83,"ESTIMATED","OBSERVATIONAL","Retrospective study based on medical records of patients with multiple myeloma, eligible for stem cell transplantation, who received, first-line, the VTD or TD combination.",[92,93],"Response, Acute Phase","Survivorship",[95,21,96,97,98],"Multiple Myeloma","Thalidomide","Acute Phase Response","Survival","2024-09-30",{"date":101,"type":102},"2024-10-02","ACTUAL",{"date":104,"type":102},"2023-11-20",{"date":106,"type":88},"2024-10-30",{"name":5,"class":6},1]